Oral Wegovy tablet from Novo Nordisk pushes weight-loss drugs into pill territory

Novo Nordisk’s new oral Wegovy tablet brings its blockbuster semaglutide weight-loss therapy into a once-daily pill, with UK regulators just clearing the way for adults with obesity or overweight and at least one weight-related condition.

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 4:13 PM ET. Details in the imprint.

Novo Nordisk is extending its weight-loss franchise from injections to pills with the new oral Wegovy tablet, a once-daily semaglutide formulation that has just been authorized by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for obesity and weight management in adults.

According to recent regulatory updates, the MHRA cleared the oral version of Wegovy on June 11, 2026 for adults with a body mass index (BMI) of 30 or higher, or between 27 and 30 if they also have at least one weight-related condition such as hypertension, dyslipidemia or type 2 diabetes, alongside a reduced-calorie diet and increased physical activity according to the MHRA announcement.

What the oral Wegovy tablet does differently

The oral Wegovy tablet takes the same active ingredient that powered Novo Nordisk’s injectable Wegovy injections - semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist - and puts it into a tablet designed for daily use, offering patients who are averse to self-injecting an alternative delivery form.

In clinical studies, oral semaglutide for weight management has shown double-digit percentage reductions in body weight on average versus lifestyle measures alone, with a safety and tolerability profile broadly consistent with injectable GLP-1 drugs, most commonly gastrointestinal side effects such as nausea, vomiting and diarrhea at the start of therapy as doses are escalated over time.

The MHRA says the oral Wegovy tablet is indicated as an adjunct to diet and physical activity for chronic weight management at specified BMI thresholds, and treatment is intended for adults only, reflecting similar positioning to the injectable Wegovy pen already marketed in the UK’s National Health Service under certain criteria as outlined in Novo Nordisk’s product communication.

Unlike weekly injections, the tablet must be taken every day on an empty stomach with a small amount of water, and patients are typically required to wait before eating or drinking to ensure adequate absorption of the peptide-based drug, a practical consideration that may shape how physicians and patients weigh the trade-off between needle-free administration and daily routine requirements.

For Novo Nordisk, the oral formulation provides another lever to defend and expand its share of the fast-growing global obesity treatment market, where rival GLP-1 drugs and next-generation incretin combinations are vying for prescriber attention and finite manufacturing capacity, and where different delivery forms can help match therapies to patient preferences and healthcare-system logistics.

Health-economics discussions are likely to follow quickly, as payers in Europe and beyond assess where an oral GLP-1 for obesity sits relative to injectable options in value-for-money terms, especially given the chronic nature of obesity treatment and the emphasis on long-term adherence to sustain weight loss and cardiometabolic benefits.

Within Novo Nordisk’s broader portfolio, Wegovy - both in injectable and now oral form - sits alongside diabetes medicine Ozempic and other semaglutide-based products such as oral diabetes pill Rybelsus, underscoring how much of the Danish group’s current and future growth is tied to the GLP-1 class and its ability to scale production, secure reimbursement and manage safety perceptions in the public debate.

Investors have closely followed any development that could extend semaglutide’s addressable market, and the arrival of an oral Wegovy tablet in a major European country adds another data point in that story, even though pricing, reimbursement decisions and potential launches in other regions such as the EU and North America will determine how economically meaningful this new dosage form becomes.

Against this backdrop, Novo Nordisk has continued to return cash to shareholders via buybacks, with its latest capital-markets update showing billions of Danish kroner in B-share repurchases as part of a 12-month program initiated in early 2026 that is designed to offset dilution from employee programs and adjust the capital structure over time as detailed in a GlobeNewswire filing.

Shares of Novo Nordisk (DK0060534915) traded on the New York Stock Exchange as NVO at around $120 on 06/14/2026, reflecting how central investors now view obesity medicines and GLP-1-based therapies to the group’s valuation and long-term growth narrative, even as competition in the category intensifies.

Oral Wegovy tablet in brief: the hard facts

• Product: Oral Wegovy tablet (semaglutide)
• Manufacturer: Novo Nordisk A/S
• Category: Flagship/Bestseller obesity treatment
• Launch date: Authorized by UK MHRA on 06/11/2026 for adults with obesity or overweight plus weight-related conditions
• MSRP / Price: UK list price not yet broadly disclosed; subject to national and local reimbursement negotiations
• Availability: Initially UK prescription market, with other regions dependent on regulatory review and payer decisions
• Target audience: Adults with BMI ?30, or BMI 27-30 with at least one weight-related comorbidity
• Key differentiator / USP: First oral GLP-1-based therapy for chronic weight management authorized in a major market, offering a needle-free alternative to weekly injections

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.